Summary Despite considerable progress in understanding tumour development. the law of growth for human tumours is still a matter of some dispute. In this study, we used large-scale mammography screening trial data to deduce the growth law of primary breast cancer. We compared the empirical tumour population size distributions of primary breast cancer inferred from these data to the distributions that correspond to various possible theoretical growth functions. From this. we showed that the data are inconsistent with the exponential, logistic and Gompertz laws, but support power law growth (exponent = 0.5). This law indicates unbounded growth but with slowing mass-specific growth rate and doubling time. In the clinical size ranges, it implies a greater decline in the mass-specific growth rate than would be predicted by the Gompertz law using the accepted parameters. This suggests that large tumours would be less sensitive to cycle-specific therapies. and be better treated first by non-cell cycle-specific agents. We discussed the use of our study to estimate the sensitivity of mammography for the detection of small tumours. For example, we estimated that mammography is about 30% less sensitive in the detection of tumours in the 1 to Flehinger. 1991 and Xu and Prorok. 1997 for theoretical discussions). Nex ertheless. the benefit of screening. especiall in youncer women (< 50 Xyears). still remains somew-hat controv-ersial (Fletcher et al. 1993 : Tabar et al. 1995 In the present w-ork. we employed extensive clinical data from large mammogaraphv screening trials that should be representatiVe of the general population. Usinc mathematical tools. we extracted from these data useful information about breast cancer growth. 
Breast cancer is the most common malignancy in wxomen. afflicting one in evers ten women in the WNestern World. Recentlv. the role of tumour grow-th dy namics in determinin-the clinical course of the disease has been re-emphasized by demonstrating howx such know-ledge can lead to more efficient treatment protocols (Crow-n. 19971 . Large-scale breast cancer screeninc mammography trials showx that significantly smaller tumours are detected in screened populations. compared wxith the control. and it is probable that the disease w-ould be better controlled if smaller tumours could be detected (Tabar et al. 1992 : see also Flehinger. 1991 and Xu and Prorok. 1997 for theoretical discussions). Nex ertheless. the benefit of screening. especiall in youncer women (< 50 Xyears). still remains somew-hat controv-ersial (Fletcher et al. 1993 : Tabar et al. 1995 : see also Flehinger et al. 1993 for lung cancer). As intersal cancer data indicate that not all prevalent tumours are detected by the screening procedure lHolmberg et al. 1986 . anv realistic e-aluation of mammographic screening efficiency must account for detection sensitix itv. panicularlv for smaller sizes.
In the present w-ork. we employed extensive clinical data from large mammogaraphv screening trials that should be representatiVe of the general population. Usinc mathematical tools. we extracted from these data useful information about breast cancer growth.
Our conclusions. corroborated by recent laboraton-. clinical and edge of size-dependent tumour growth rates can help evaluate the relative sensitivits of mammography as a function of tumour size. This mav be useful for determining! the optimal interval betwxeen subsequent screenings. In addition. our result may suggest w ayvs to improve chemotherapy treatment protocols.
Previous attempts to estimate human breast cancer growth rates as a function of size w ere mostly based on those cases in w hich the primary tumour can be seen in retrospect in previous mammograms. This type of analysis is confined only to serv limited and. possiblY. not representatixe g roups of patients (Gershon-Cohen et al. 1963 : Heuser et al. 1979 : Foumier et al. 1980 : Peer et al. 1993 : Spratt et al. 1993 . Several putative lawxs for tumour growth hasve been proposed. based on this tsype of human study and on experiments in animals. Each of these implies different model-specific dynamics of tumour g2rowth (Mendelsohn. 1963 : Laird. 1965 : Steel and Lamerton. 1966 : Norton and Simon. 1976 : Norton. 1988 ).
The most commonly used tumour growth model is exponential growth. in wxhich the cells divide at a constant rate independent of tumour size and age. A more general equation. which represents a ven-broad family of grrowth rates (including the exponential). is the powxer lawx differential equation:
>-here v denotes the tumour mass. k is a constant of groxxth and the exponent 3 is an indicator of the tumour's mode of arowth l(when 3 = 0. the growxth is linear. wxhen 3 = 1 the groxxth is exponential. etc.). The solution of the power growth law (equation 1) for . 1 is given by:
where c is a constant. Equation 1 was introduced more than three decades ago by Mendelsohn. and was shown at that time to fit observed growth curves of experimental animal mammary tumours (Mendelsohn. 1963 : Dethlefsen et al. 1968 .
A different school of thought is represented by the sigmoidal family of functions. such as the logistic and Gompertz growth laws.
In these laws it is assumed that tumoral and/or host constraints gradually inhibit tumour growth to an asymptotic value. Illustrated in Figure IA are the growth curves that represent the power law model. with 5 = 1 (exponential growth) and 0 = 0.5 (parabolic growth). as well as Gompertz growth. The exponential and Gompertz curves have been plotted using accepted parameters drawn from the literature (Foumier et al, 1980; Norton. 1988) . Figure lB shows that these models predict remarkably different time-dependent changes in the mass-specific tumour growth rate. Determining which function is most suitable for describing pnmary breast cancer growth is therefore warranted.
METHODS
Calculating the probability that a tumour is detected before screening
Consider a tumour of size s that would be present in a natural population with no removals. This tumour in the actual screen population. might be detected and removed before screening; we wish to calculate the probability p of this detection. Let t(v) be the probability density (with respect to tumour size) that a tumour is detected at size v. Then the probability of detection before the tumour reaches size s is:
We can estimate the value of this integral using the data for the control population. These data consist of the number n, of tumours detected between sizes v k and vk. for each of the m size categories. k = 1. 2. m. The probability density j. in the kt size class is thus approximately:
where n = E n is the total number of tumours detected in the t=l k control population. The tumour of size s will be on average approximately in the middle of its size category k5. Thus. the above integral can be approximated as: For Gomperz growth a = 0.66 and k = 19 (Norton, 1988) (6) where C is a constant chosen to normalize the probability density to one. In the case of power law growth (equation 1). fly) = kv{. (10) where K is the limiting size of the tumour and r is a constant (Edelstein-Keshet. 1988) . Inserting this into equation 6 gives:
The logistic differential equation is: 
RESULTS
We focused our analysis on the size distribution of tumours found in the first screen of the two-county Swedish mammography trial. which is one of the largest and most detailed studies of its kind (Tabar et al, 1992) . Other published mammography screening trials (Thomas et al, 1984; Fagenberg et al. 1985; Burbenne et al. 1992; Peer et al. 1994; de Koning et al. 1995) are less detailed, but can provide collaborative information about the tumour size distribution (Table 1) .
Our first aim was to reconstruct from the two-county Swedish mammography data the natural tumour size distribution in the population, i.e. what the size distribution would have been had there been no removals before the first screen. To this end. we employed the distribution of tumour sizes at detection in the twocounty Swedish study's large corresponding control group. We reconstructed the natural tumour size distribution by estimating the probability, p, that a tumour of a given size category would have been detected without screening (see Methods). and then divided the number of tumours detected by mammography in each category by I -p. We excluded from the analysis the smallest (< 1 cm) size category because of reduced mammography sensitivity in small tumours (Feig et al. 1977 : Yaffe et al. 1993 ). As the probability of self-detection in the largest size category (> 5 cm) is close to 1. dividing by 1 -p would produce a number extremely sensitive to the exact value ofp. and thus be unreliable: therefore. this size category was excluded as well (Table 1) . We assumed that in the 1-to 5-cm range there is little variation in detection sensitivity (with the possible exception of the 1-to 1.5-cm category). Hence, we took the probability of detection in these size categories as constant.
Britsh Joumal of Cancer (1998) obtained with a siope --= -0.42; (,e = 0.97). The Gonpertz law was fitted using a liming size of 3100 ml (Norton, 1988 Swedish two-county (6 years) (Fagerberg et al, 1985) NiTmegen (Peer et al, 1994) (Norton. 1988 : Spratt et al. 1993 ). Most of the non-linearity in the two-county Swedish data is due to the density of the lowest size category (1-1.5 cm). where the sensitivity of the mammography may be less than for larger tumours. Excluding this point gives a slightly higher exponent (1 = 0.53: r' = 0.99). Thus. the evidence indicates that primary breast cancer growth is parabolic (power law growth. 1 -0.5).
Verification of the result using indonent screening tals We verified our result by using data from other published mammography screening trials: only studies that contain sufficient information for analysis were included. Our analysis of these data. including an earlier report of the same Swedish study discussed above (Fagerberg et al. 1985) . give consistent results: the data in all cases are compatible with power law growth. with 1 between 0.32 and 0.55 (Table 1 ). The slopes of the UK (Thomas et al, 1984) and British Columbia (Burhenne et al, 1992) Spratt (1993) . are less significant in the clinical size ranges than those predicted by parabolic growth ( Figure 1B ). This may imply that the response of breast cancer to chemotherapy may be different than would be suggested by the Norton-Simon model that assumes Gompertz growth (Norton and Simon. 1986 ).
There is substantial evidence at the cellular level of a decline in the mass-specific growth rate as tumours increase in size. Studies of the cytokinetics of both human breast cancer and experimental tumours show that the thymidine labeling index (TLI) declines in larger tumours. indicating that the fraction of cells that are actively growing is decreasing (Schiffer et al, 1979: Meyer and Coplin. 1988 This study also may have implications for breast cancer cell kinetic parameter estimation. For instance, the tumour's potential doubling time and cell loss factor. which may be useful for dose calculation in radiotherapy. are calculated under the assumption of a constant cell cycle time and an exponential tumour growth. respectively (Steel. 1967 . 1989 : Bertuzzi et al. 1995 . If. as our study suggests. tumours follow parabolic growth. it would be necessary instead to estimate the patient-specific growth constant. k (equation 1). which is probably highly variable (Fourmier et al. 1980 ). Alternating chemotherapy regimens. proposed by Goldie and Coldman for mi im zing the risk of drug resistance (Goldie and Coldman. 1979) . have been the rationale of numerous anti-cancer protocols for the last 20 years. Our findings may imply an alternative strategy. If. as our results suggest. there is a significant decline in the percentage of actively dividing cells in large tumours ( Figure 1B ). these tumours would be less sensitive to cyclespecific therapies. Therefore. they may be better treated first with rather broader activity antineoplastic drugs. such as anthracyclines or alkylating agents. This may be an explanation for the observation that alternating the non-cell cycle-specific drug. doxorubicin.
with CMF (cyclophosphamide. methotrexate. 5-fluorouracil. the last two drugs being cell cycle specific) is significantly inferior to a sequential chemotherapy protocol with doxorubicin as the first drug for high-risk (i.e. large tumour burden) breast cancer (Bonadonna et al. 1995) .
Our results refer to the growth of untreated mou only and their relevance for the growth pattems of tumours under treatment remains to be investigated. Nevertheless.it is interesting to note that the relative benefit of accelerated irradiation strategy (Corvo et al. 1995) may be explained in part by our results. If irradiated tumours are subject to a similar power law growth. according to which as tumours shrink under ratment their growth fraction increases, then the latter period of therapy should be more aggressive.
The optimal growth pattems of interacting cell assemblies have recenfly been shown to follow parabolic or other power laws (Drasdo et al, 1995) . These theoretical results corroborate our analysis of clinical data. and imply that power growth law may have greater generality than just to mammary tumours. Our very preliminary analyses of thyroid cancer and renal cell carcinoma screening data suggest that the growth rate of these tumours may also follow a power law. More empirical evidence is needed to assess the universality of power law growth and its usefulness in the control of cancer.
